Telephone:
+61 7 3646 5820
The PRIMARY trial investigates the additive diagnostic value of the PET PSMA tracer – What’s its ability to reduce unnecessary prostate biopsies in men being investigated for prostate cancer.
We asked lead researcher Dr Matthew Roberts to offer some insight into the project and how HIRF is contributing to clinical innovation.